Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Endosonics(eson) -- Ignore unavailable to you. Want to Upgrade?

To: dr.john who wrote (166)	12/20/1998 11:31:00 AM
From: Lenny Ehn	Read Replies (1) \| Respond to of 205

Good News regarding the joint venture: Quick Results! Hope this results in some stock movement! Len RANCHO CORDOVA, Calif.--(BW HealthWire)--Dec. 14, 1998--An intravascular ultrasound-guided stent delivery system jointly developed by EndoSonics Corporation (NASDAQ:ESON) and JOMED AB of Helsingborg, Sweden, was successfully deployed during the second Cardiovascular Summit in Rotterdam, The Netherlands, December 8 - 12. During a live case transmission, cardiologists at the Thorax Center of Erasmus University in Rotterdam used the integrated therapeutic device to perform primary stenting on a 73-year-old patient, the first use of the system developed by EndoSonics and JOMED under an agreement in principle reached last September. "Integrating this intravascular imaging technology on a stent delivery system provides an efficient and effective tool for the physician to optimize stent placement, which we know improves clinical outcome," said Professor Patrick W. Serruys, a noted interventional cardiologist and principal organizer of the Cardiovascular Summit. The therapeutic device integrates EndoSonics' ultrasound catheter with a JOMED stent and balloon. JOMED and EndoSonics will market the new product through JOMED's direct operations and through joint partners in several European countries. "This initial demonstration marks the end of the system's developmental phase, which was completed quickly and efficiently in less than three months," noted EndoSonics President and Chief Executive Officer Reinhard J. Warnking. "With this breakthrough therapeutic device, physicians have the comfort of a premounted stent, combined with the ability to immediately assess the results of the procedure and complete any necessary refinements before removing the catheter." Tor Peters, JOMED President and CEO, called the combined therapeutic device's introduction "a major advancement in image-guided therapy in Europe," adding that the product is expected to be introduced during the first quarter of 1999 following regulatory (CE mark) approval.